Medtronic (MDT) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Medtronic (MDT)

MDT 90.41

0.0%

Nov 5 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Thomas J Pittman who started this subject	10/5/2001 11:26:22 AM
From: Jack Hartmann	Read Replies (1) of 687

S&P on MDT MEDTRONIC last week reiterated its goals of 15% revenue growth and per-share earnings growth in the high teens. We believe that the medical device maker’s objectives are achievable due to favorable prospects in the spinal, neu-rostimulation and diabetes areas, as well as because of new products in the car-diac rhythm management, congestive heart failure and stent areas. We also think that the company will be able to expand its gross margin and that the for-eign exchange headwinds it has faced will somewhat abate. On the negative side, Medtronic’s vascular business remains most vulnerable to competition. We are leaving our earnings estimate for fiscal 2002 (ending April) at $1.22 a share and see a 16% gain to $1.42 in fis-cal 2003. We believe that the premium that markets will rebound within six to 12 months. Jack

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next